CARIPRAZINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CARIPRAZINE HYDROCHLORIDE (CARIPRAZINE HYDROCHLORIDE).
Cariprazine is a partial agonist at dopamine D3 and D2 receptors, with higher affinity for D3 receptors, and a partial agonist at serotonin 5-HT1A receptors; it is an antagonist at 5-HT2A and 5-HT2B receptors.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6 to active metabolites (desmethylcariprazine and didesmethylcariprazine). |
| Excretion | Primarily hepatic metabolism via CYP3A4 and CYP2D6, with 60% excreted in feces (mostly as metabolites) and 30% in urine (mostly as metabolites). Less than 1% excreted unchanged. |
| Half-life | Terminal elimination half-life: 2–5 days (48–120 hours) for cariprazine and its major active metabolites (desmethylcariprazine, didesmethylcariprazine). The long half-life supports once-daily dosing and allows for gradual dose titration. |
| Protein binding | Approximately 91–97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 9 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral bioavailability: Estimated to be high due to good absorption, though absolute bioavailability not determined; peak plasma concentrations reached in 3–6 hours post-dose. Food (high-fat meal) does not significantly affect AUC or Cmax of cariprazine. |
| Onset of Action | Oral administration: Onset of antipsychotic effect typically within 1–2 weeks, with full therapeutic effect often requiring 3–6 weeks due to slow dose titration and accumulation of active metabolites. |
| Duration of Action | Single oral dose: Antipsychotic effects persist for at least 24 hours due to the long half-lives of parent drug and its active metabolites, allowing once-daily dosing. Therapeutically, steady state is reached after 2–3 weeks. |
1.5 mg orally once daily, with a recommended titration starting at 1.5 mg on day 1, increased to 3 mg on day 2, then 4.5 mg on day 3, and 6 mg on day 4; target dose range: 1.5–6 mg once daily, with a maximum of 6 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min/1.73 m2. For GFR <30 mL/min/1.73 m2 or end-stage renal disease, use is not recommended due to lack of data. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: maximum recommended dose is 3 mg once daily. Child-Pugh Class C: use is not recommended. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established; no specific dosing recommendations available. |
| Geriatric use | No specific dose adjustment required; however, elderly patients may be more sensitive to adverse effects (e.g., orthostatic hypotension, somnolence). Initiate at lower end of dosing range and titrate slowly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CARIPRAZINE HYDROCHLORIDE (CARIPRAZINE HYDROCHLORIDE).
| Breastfeeding | Present in breast milk at low levels; infant M/P ratio unknown. Limited case reports suggest no adverse effects in breastfed infants, but monitor for sedation and EPS. Caution advised, especially in preterm or ill neonates. |
| Teratogenic Risk | Limited human data; first trimester: insufficient evidence for major malformations; second/third trimester: risk of extrapyramidal symptoms (EPS) and neonatal withdrawal (e.g., agitation, hypertonia, tremors) with late-gestation exposure. Animal studies show no teratogenicity at clinically relevant doses. |
■ FDA Black Box Warning
Increased mortality in elderly patients with dementia-related psychosis.
| Serious Effects |
["Known hypersensitivity to cariprazine or any components of the formulation"]
| Precautions | ["Increased mortality in elderly patients with dementia-related psychosis","Suicidal thoughts and behaviors","Neuroleptic malignant syndrome (NMS)","Tardive dyskinesia","Metabolic changes (hyperglycemia, dyslipidemia, weight gain)","Leukopenia, neutropenia, agranulocytosis","Orthostatic hypotension and syncope","Seizures","Body temperature dysregulation","Dysphagia","Cognitive and motor impairment"] |
| Food/Dietary | Avoid grapefruit juice as it may increase cariprazine exposure. No other significant food interactions; administer with or without food. However, high-fat meals may slightly reduce absorption, but no dose adjustment is needed. |
Loading safety data…
| Fetal Monitoring | Monitor maternal for EPS, akathisia, metabolic changes (weight, glucose, lipids); fetal/neonatal: monitor for EPS, withdrawal (lethargy, feeding difficulty, hypertonia), and adverse pregnancy outcomes (e.g., preterm birth, low birth weight). Consider therapeutic drug monitoring if available. |
| Fertility Effects | Animal studies show no significant impairment of fertility; however, hyperprolactinemia (dose-dependent) may occur, potentially affecting menstrual cycle and fertility in females. Human data limited. |
| Clinical Pearls | Cariprazine hydrochloride is a dopamine D3-preferring D2/D3 receptor partial agonist, which may confer advantages in negative symptoms and cognitive deficits of schizophrenia. Titrate slowly to minimize akathisia and restlessness; initial dose 1.5 mg/day, increase by 1.5 mg increments. Monitor for orthostatic hypotension, especially early in treatment. Avoid use in patients with dementia-related psychosis due to increased mortality risk. |
| Patient Advice | Take this medication exactly as prescribed; do not change dose without consulting your doctor. · You may experience dizziness or lightheadedness upon standing; rise slowly from sitting or lying positions. · Notify your doctor immediately if you develop uncontrollable muscle movements, especially of the face, tongue, or jaw. · Avoid alcohol and grapefruit juice while taking this medication. · If you become pregnant or plan to become pregnant, inform your doctor; this medication may cause extrapyramidal symptoms in the newborn. · Do not drive or operate heavy machinery until you know how this drug affects you; it may cause drowsiness or dizziness. |